Dorothy R Barnard

Summary

Affiliation: Nova Scotia
Country: Canada

Publications

  1. ncbi Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation
    Dorothy R Barnard
    Dalhousie University, Halifax, NS
    Blood 100:427-34. 2002
  2. ncbi Development of disease-specific health-related quality-of-life instruments for children with immune thrombocytopenic purpura and their parents
    Dorothy Barnard
    IWK Health Center, Dalhousie University, 5850 University Avenue, Halifax, Nova Scotia B3J 3G9, Canada
    J Pediatr Hematol Oncol 25:56-62. 2003
  3. ncbi Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology Group
    Dorothy R Barnard
    IWK Health Centre, Halifax, Nova Scotia, Canada
    Pediatr Blood Cancer 49:17-22. 2007
  4. ncbi The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase
    Lesleigh S Abbott
    Department of Pediatrics, Dalhousie University and Isaak Walton Killam Health Centre, Halifax, NS, Canada
    Blood 114:5146-51. 2009
  5. ncbi Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival
    Steven Neudorf
    American Family Life Assurance Company AFLAC Cancer Center, Emory University Children s Healthcare, Atlanta, GA, USA
    Blood 103:3655-61. 2004
  6. ncbi Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891
    Alan S Gamis
    Section of Hematology Oncology Blood and Marrow Transplantation, Children s Mercy Hospital and Clinics, 2401 Gillham Rd, Kansas City, MO 64108, USA
    J Clin Oncol 21:3415-22. 2003
  7. ncbi Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group
    William G Woods
    AFLAC Cancer Center, Emory University Children s Healthcare, Atlanta, GA, USA
    J Clin Oncol 20:434-40. 2002
  8. ncbi Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children's Cancer Group
    Kathryn E Dusenbery
    University of Minnesota, Minneapolis, USA
    J Pediatr Hematol Oncol 25:760-8. 2003
  9. ncbi Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961
    Draga Barbaric
    Division of Hematology Oncology BMT, BC s Children s Hospital, Vancouver, BC, Canada
    Blood 109:2314-21. 2007
  10. ncbi Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group
    Beverly J Lange
    University of Pennsylvania School of Medicine and The Children s Hospital of Philadelphia, Division of Oncology, Philadelphia, PA, USA
    Blood 111:1044-53. 2008

Detail Information

Publications10

  1. ncbi Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation
    Dorothy R Barnard
    Dalhousie University, Halifax, NS
    Blood 100:427-34. 2002
    ..The findings of this study confirm that most children with tMDS/tAML have disease resistant to current therapies. Standard-timing induction appears less effective for this population...
  2. ncbi Development of disease-specific health-related quality-of-life instruments for children with immune thrombocytopenic purpura and their parents
    Dorothy Barnard
    IWK Health Center, Dalhousie University, 5850 University Avenue, Halifax, Nova Scotia B3J 3G9, Canada
    J Pediatr Hematol Oncol 25:56-62. 2003
    ..ITP is usually a self-limited disorder. With current controversy over management approaches, an evaluation of the disease burden experienced by the child and the family may assist with the assessment of alternative treatment approaches...
  3. ncbi Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology Group
    Dorothy R Barnard
    IWK Health Centre, Halifax, Nova Scotia, Canada
    Pediatr Blood Cancer 49:17-22. 2007
    ..Myelodysplastic syndromes (MDS), acute erythroleukemia (FAB M6), and acute megakaryocytic leukemia (FAB M7) have overlapping features...
  4. ncbi The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase
    Lesleigh S Abbott
    Department of Pediatrics, Dalhousie University and Isaak Walton Killam Health Centre, Halifax, NS, Canada
    Blood 114:5146-51. 2009
    ..Neither FFP nor CRY protected against CNST, suggesting prophylaxis is unwarranted for unselected ALL patients. However, prophylactic replacement for HR patients in induction may be cost-effective...
  5. ncbi Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival
    Steven Neudorf
    American Family Life Assurance Company AFLAC Cancer Center, Emory University Children s Healthcare, Atlanta, GA, USA
    Blood 103:3655-61. 2004
    ..014) were associated with improved relapse-free survival (RFS). Our results show that children older than 10 years are at higher risk for developing severe GVHD; acute GVHD is associated with favorable RFS...
  6. ncbi Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891
    Alan S Gamis
    Section of Hematology Oncology Blood and Marrow Transplantation, Children s Mercy Hospital and Clinics, 2401 Gillham Rd, Kansas City, MO 64108, USA
    J Clin Oncol 21:3415-22. 2003
    ..To determine the outcome of children with Down syndrome (DS) and acute myeloid leukemia (AML) receiving standard timing chemotherapy without bone marrow transplantation (BMT), with determination of prognostic factors...
  7. ncbi Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group
    William G Woods
    AFLAC Cancer Center, Emory University Children s Healthcare, Atlanta, GA, USA
    J Clin Oncol 20:434-40. 2002
    ..We report the first large prospective study of children with myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML) treated in a uniform fashion on Children's Cancer Group protocol 2891...
  8. ncbi Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children's Cancer Group
    Kathryn E Dusenbery
    University of Minnesota, Minneapolis, USA
    J Pediatr Hematol Oncol 25:760-8. 2003
    ..To describe features of patients with acute myeloid leukemia presenting with extramedullary leukemic tumors (EML)...
  9. ncbi Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961
    Draga Barbaric
    Division of Hematology Oncology BMT, BC s Children s Hospital, Vancouver, BC, Canada
    Blood 109:2314-21. 2007
    ..There was no significant outcome difference between DS-associated AML-M0 and non-M0 children. This study suggests that intensively treated non-DS-associated AML-M0 children have an inferior outcome compared with children with non-M0 AML...
  10. ncbi Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group
    Beverly J Lange
    University of Pennsylvania School of Medicine and The Children s Hospital of Philadelphia, Division of Oncology, Philadelphia, PA, USA
    Blood 111:1044-53. 2008
    ..No new agent improved outcomes; experience may have contributed to better results time...